Overview

Proleukin and Rapamune in Type 1 Diabetes

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

This is a phase I trial in individuals who have been diagnosed with type 1 diabetes within the previous 3-48 months. The study is testing whether two immune system modifying drugs are safe when used in combination and if they have immune altering effects that indicate they can halt the progression of type 1 diabetes progression.

Phase:

Phase 1

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator:

Immune Tolerance Network (ITN)

Treatments:

Aldesleukin
Everolimus
Sirolimus